Vanda Pharmaceuticals vs Xeris Biopharma
VNDA and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VNDA and XERS compare
Xeris Biopharma is the larger company, worth 13 times as much as Vanda Pharmaceuticals ($3.1B against $230M).
Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 8.1% for Vanda Pharmaceuticals).
Xeris Biopharma keeps more of each dollar of sales as profit, with a net margin of −5.1% compared with −120% at Vanda Pharmaceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VNDA | XERS |
|---|---|---|
| Size and price | ||
| Market cap | $230M | $3.1B |
| Share price | $3.81 | $16.80 |
| Change, 1 year | −12.4% | 134% |
| Change, 5 years | −77.0% | 674% |
| Beta (5Y) | 0.78 | 0.27 |
| Employees | 533 | 435 |
| StockData Score | ||
| Total score | 10 | 10 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.0× (better) | 9.1× |
| P/B | 1.2× | – |
| EV/EBITDA | – | 84.2× |
| FCF yield | −60.8% | – |
| Fair value | $8.53 | – |
| Margin of safety | 55.3% | – |
| Growth | ||
| Revenue growth (TTM) | 8.1% | 36.3% (better) |
| Revenue growth, 5Y average | −2.7% | 70.2% (better) |
| Profitability | ||
| Gross margin | 93.6% (better) | 86.6% |
| Operating margin | −77.6% | 10.9% (better) |
| Net margin | −120% | −5.1% (better) |
| FCF margin | −61.0% | – |
| Return on equity | −82.5% | – |
| Return on invested capital | −52.6% | 22.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | 3.45 |
| Interest coverage | – | 1.3× |
| Current ratio | 1.54 (better) | 1.45 |
| Altman Z-score | −1.85 | 3.33 (better) |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.2% | 59.4% |
| Held by insiders | 9.2% | 5.2% |
| Insider net buying, 12 months | −$2.8M (better) | −$5.8M |
| Short interest, % of float | 13.9% | 5.2% |
Go deeper
- VNDA stock overview
- VNDA income statement
- VNDA valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.